paclitaxel

P2, N=90, Not yet recruiting, Akeso

P4, N=2, Terminated, Ottawa Hospital Research Institute | Completed --> Terminated; The study did not meet the pilot feasibility endpoints and was formally closed to accrual prematurely on February 8, 2017.

P2, N=408, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed

Drug sensitivity analysis showed that the risk score was significantly correlated with the sensitivity to various chemotherapeutic drugs (e.g., Methotrexate, Paclitaxel). This study established a reliable prognostic risk scoring model for HCC by screening differentially expressed glycolysis-related miRNAs, which effectively distinguishes between high-risk and low-risk patients and predicts patient survival. Additionally, the model is closely associated with the immune microenvironment and drug sensitivity, offering strong support for personalized treatment and clinical decision-making in HCC.

Co-culture spheroids exhibited higher resistance to paclitaxel as compared to monoculture BMBC spheroids. Our 3D co-culture platform successfully recapitulated to an extent the pro-tumorigenic, immunosuppressive, therapy resistant TME, and tumor immune heterogeneity of BMBC and could contribute towards understanding tumor immune interactions in BMBC.

These results revealed dexamethasone could promote chemoresistance and stemness in lung cancer by inducing nuclear-translocation of GR/β-catenin complex. In the long run, more cautions are needed when glucocorticoids are prescribed to patients during chemotherapy.

Furthermore, cephalochromin enhanced the cytotoxicity of paclitaxel and doxorubicin, showing additive synergistic interactions. In conclusion, our study provides compelling evidence of cephalochromin's antineoplastic activity in breast cancer, highlighting its potential to improve treatment outcomes. Further preclinical studies are warranted to validate their therapeutic efficacy and safety.

P3, N=172, Not yet recruiting, Asan Medical Center | Initiation date: Jun 2025 --> Jan 2026

Epithelial ovarian carcinoma, the deadliest gynecological malignancy, frequently develops treatment resistance through polyploid giant cancer cells (PGCCs) that typically emerge after carboplatin-paclitaxel chemotherapy. Our findings establish that the cytoplasmic SIRT1/β-catenin axis contributes to PGCC stemness, elucidating a novel mechanism underlying chemoresistance. Therefore, targeting cytoplasmic SIRT1 represents a promising therapeutic strategy to overcome PGCC-mediated resistance in this lethal carcinoma.

P3, N=320, Not yet recruiting, Genfleet Therapeutics (Shanghai) Inc.

Combining atezolizumab with bevacizumab and chemotherapy did not significantly improve OS or PFS in patients with recurrent ovarian cancer ineligible for platinum. The safety profile was as expected from previous experience with these drugs.

The combination treatment inhibited PI3K, AKT, and STAT3 expressions, thereby suppressing proliferation and inducing proapoptotic protein expression in HGT-1 cells. Therefore, the combination of MRN and PTX could serve as a therapeutic approach for malignant GC treatment.